bexarotene has been researched along with ATLL in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, A; Benoit, B; Cha, XY; Fakharzadeh, SS; Kim, EJ; Lin, JH; Nasta, S; Richardson, SK; Rook, AH; Seykora, J; Wysocka, M; Zafar, S | 1 |
| Foss, F; Gorgun, G | 1 |
| Budgin, JB; Junkins-Hopkins, JM; Kim, EJ; Lee, J; Miller, WT; Richardson, S; Rook, AH; Vittorio, CC | 1 |
3 other study(ies) available for bexarotene and ATLL
| Article | Year |
|---|---|
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor.
Topics: Bexarotene; Drug Resistance, Neoplasm; Humans; Leukemia-Lymphoma, Adult T-Cell; Lymph Nodes; Male; Middle Aged; Recurrence; Retinoid X Receptor alpha; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes | 2008 |
Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
Topics: Adjuvants, Immunologic; Alitretinoin; Antineoplastic Agents; B-Lymphocytes; Bexarotene; Diphtheria Toxin; Gene Expression Regulation; Humans; Interleukin-2; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Interleukin-2; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; Retinoids; T-Lymphocytes; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Cells, Cultured | 2002 |
Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1.
Topics: Administration, Oral; Bexarotene; Biopsy, Needle; Blood Chemical Analysis; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Human T-lymphotropic virus 1; Humans; Immunohistochemistry; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Recombinant Proteins; Risk Assessment; Tetrahydronaphthalenes; Tomography, X-Ray Computed; Treatment Outcome | 2005 |